Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08ZEM
|
|||
| Drug Name |
Quinazoline derivative 11
|
|||
| Synonyms |
PMID26936077-Compound-22
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Patented | [1] | |
| Cirrhosis [ICD-11: DB93] | Patented | [1] | ||
| Gastrointestinal disease [ICD-11: DE2Z] | Patented | [1] | ||
| Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Patented | [1] | ||
| Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Patented | [1] | ||
| Company |
NeoPharm Co. Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H14BrN3O3S
|
|||
| Canonical SMILES |
COC1=CC(=C(C=C1)Br)C(=O)NN2C(=NC3=CC=CC=C3C2=O)C4=CC=CS4
|
|||
| InChI |
1S/C20H14BrN3O3S/c1-27-12-8-9-15(21)14(11-12)19(25)23-24-18(17-7-4-10-28-17)22-16-6-3-2-5-13(16)20(24)26/h2-11H,1H3,(H,23,25)
|
|||
| InChIKey |
SIPGYZVTRHQPRD-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proteinase activated receptor 2 (PAR2) | Target Info | Antagonist | [1] |
| Target's Patent Info | Proteinase activated receptor 2 (PAR2) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| African trypanosomiasis | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.